Aarti Pharmalabs Limited (NSE:AARTIPHARM)

Market Cap	72.18B
Revenue (ttm)	21.25B
Net Income (ttm)	2.72B
Shares Out	90.63M
EPS (ttm)	30.04
PE Ratio	26.51
Forward PE	n/a
Dividend	3.50 (0.44%)
Ex-Dividend Date	Feb 14, 2025

Volume	306,229
Average Volume	480,967
Open	798.95
Previous Close	795.25
Day's Range	787.40 - 812.95
52-Week Range	497.05 - 837.25
Beta	-0.65
RSI	60.18
Earnings Date	May 12, 2025

About Aarti Pharmalabs

Aarti Pharmalabs Limited, together with its subsidiaries, engages in the manufacture and sale of active pharmaceutical ingredients, pharmaceutical intermediates, and xanthine derivatives in India and internationally. The company offers active pharmaceutical ingredients for various therapeutic areas, such as cardiovascular, anti-asthmatic, anti-cancer, anti-coagulant, anti-diabetic, arthritis, central nervous system (CNS) agents, skincare, overactive bladder, calcimimetic, decongestant, anti-thalassaemic, analgesic, and ophthalmologic medication...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2019
• Employees: 2,095
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: AARTIPHARM

Financial Performance

In 2024, Aarti Pharmalabs's revenue was 21.25 billion, an increase of 14.71% compared to the previous year's 18.53 billion. Earnings were 2.72 billion, an increase of 25.59%.